Literature DB >> 28128715

Adoptive cell therapy: past, present and future.

Jonathan E Cohen1, Sharon Merims1, Stephen Frank1, Roni Engelstein1, Tamar Peretz1, Michal Lotem1.   

Abstract

The immune system is a potent inhibitor of tumor growth with curative potential, constituting in many eyes the future of antineoplastic therapy. Adoptive cell therapy (ACT) is a form of immunotherapy in which autologous cancer-cognate lymphocytes are expanded and modified ex vivo and re-infused to combat the tumor. This review follows the evolvement of ACT and treatment protocols, focusing on unresolved dilemmas regarding this treatment while providing evidence for its effectiveness in refractory patients. Future directions of ACT are discussed, in particular with regard to genetic engineering of autologous cells, and the role of ACT in the era of checkpoint inhibitors is addressed.

Entities:  

Keywords:  adoptive cell therapy; cancer immunotherapy; tumor-infiltrating lymphocytes

Mesh：

Substances：

Year:  2017        PMID： 28128715     DOI： 10.2217/imt-2016-0112

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  12 in total

Review 1.  The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.

Authors:  Yongjiang Li; Ciceron Ayala-Orozco; Pradipta Ranjan Rauta; Sunil Krishnan
Journal:  Nanoscale       Date:  2019-09-18       Impact factor: 7.790

2.  Silica Nanocapsules with Different Sizes and Physicochemical Properties as Suitable Nanocarriers for Uptake in T-Cells.

Authors:  Raweewan Thiramanas; Shuai Jiang; Johanna Simon; Katharina Landfester; Volker Mailänder
Journal:  Int J Nanomedicine       Date:  2020-08-13

3.  LAP+CD4+T cells regulate the anti-tumor role of CIK cells in colorectal cancer through IL-10 and TGF-β.

Authors:  Wu Zhong; Chuanfa Fang; Hongquan Liu; Lei Zhang; Xiaofei Zhang; Junqiao Zhong; Xianping He; Leichang Zhang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

4.  A Nanobody Against Cytotoxic T-Lymphocyte Associated Antigen-4 Increases the Anti-Tumor Effects of Specific CD8+ T Cells.

Authors:  Zhuoran Tang; Fengzhen Mo; Aiqun Liu; Siliang Duan; Xiaomei Yang; Liu Liang; Xiaoqiong Hou; Shihua Yin; Xiaobing Jiang; Natalia Vasylieva; Jiexian Dong; Bogdan Barnych; Bruce D Hammock; Xiaoling Lu
Journal:  J Biomed Nanotechnol       Date:  2019-11-01       Impact factor: 3.641

Review 5.  Novel and emerging therapies for B cell lymphoma.

Authors:  Sabarish Ayyappan; Kami Maddocks
Journal:  J Hematol Oncol       Date:  2019-07-25       Impact factor: 17.388

Review 6.  Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy.

Authors:  Lin Shui; Xi Yang; Jian Li; Cheng Yi; Qin Sun; Hong Zhu
Journal:  Front Immunol       Date:  2020-01-17       Impact factor: 7.561

7.  Cellular Uptake of siRNA-Loaded Nanocarriers to Knockdown PD-L1: Strategies to Improve T-cell Functions.

Authors:  Raweewan Thiramanas; Mengyi Li; Shuai Jiang; Katharina Landfester; Volker Mailänder
Journal:  Cells       Date:  2020-09-07       Impact factor: 6.600

Review 8.  Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication.

Authors:  Meysam Mosallaei; Miganoosh Simonian; Naeim Ehtesham; Mohammad Reza Karimzadeh; Nasim Vatandoost; Babak Negahdari; Rasoul Salehi
Journal:  Cancer Gene Ther       Date:  2020-05-18       Impact factor: 5.987

Review 9.  Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.

Authors:  Xingchun Gao; Yajing Mi; Na Guo; Hao Xu; Lixian Xu; Xingchun Gou; Weilin Jin
Journal:  Front Immunol       Date:  2017-07-06       Impact factor: 7.561

Review 10.  Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.

Authors:  Robert D Carlson; John C Flickinger; Adam E Snook
Journal:  Toxins (Basel)       Date:  2020-04-09       Impact factor: 4.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.